SOHM Inc (SHMN)

[ChartTRACKER]

$SHMN: MPSTOCK: It's NOT your fault. Mktg needs to do a better job.
URGENCY is IMPORTANT.

>>I just don’t see a catalyst right now that will move the price up
1. The CATALYSTS have been clearly communicated 👇️

The company is actively exploring, negotiating, and collaborating with several Japanese companies to expand its business.

This expansion includes the utilization of gene-editing technology called ABBIE, as well as licensing opportunities.

The management remains committed to…

— SOHM, Inc. (@sohminc) March 19, 2024

And we're EXPECTING developments [not just updates in a few weeks]; ABBIE results have been
presented at AACR24, peer reviewed pubs.

2. This is NOT some '10' yr old tech [as some '10' yr. old brain stated].The person is CLUELESS about
the SINGLE most IMPORTANT thing for Gene-Editing [Plant /Human use], i.e., Off-Target Limitations & unwanted mutations resulting in cancer etc.
Can't use ChatGPT & think they know everything! It's an Experiential acquisition.
Moreover, '10' yr. Old tech in Gene-Editing is ONLY now coming to fruition, via FDA approvals.
The ONE thing that can't be done is to predict Success/Failure, by how some company sold off ABBIE, B/C they
were sure it won't work! It takes Several Hundred $Millions to find out how & why it would work, in one area vs others.
TIME, $ & Statistics are key,NOT some dumb-A** opinion, about "10" yr old tech.
That's the most dumbest thing I've heard here!
We're talking about Permutations & Combinations in the 10's of Millions! And that's why there is a PROTOCOL for DESIGN, TESTING & V&V
And what's good in one area, may fail in another area [case in point, Genentech's AVASTIN, failed as a breast cancer drug, but is a major success in
many other therapies...making > $5B for Roche every year! This is just ONE Drug!

**********************************************************************************************************
ABBIE is resolving off-target edits by using the latest advances in:
-- Enzymes,
-- Guide RNA and
-- Cell or tissue-specific delivery.

ABBIE is able to significantly improve gene-editing precision with improved systems for DNA insertion.
ABBIE’s cell engineering tools and systems can reduce incidences of off-target edits by:
-- not inducing double-stranded breaks
**********************************************************************************************************